G’day Sid. I believe they will spell out reduction points...

G’day Sid. I believe they will spell out reduction points clearly. If is the same as or better than Somervert it doesn’t matter as the therapeutic end-point for Acromegaly has been reached… in which case significant value has been added – this is undeniable and prepare for massive upside in the share price and recognition in value of the company imo.

Also, those quoting value to bring drugs to market are obviously aware this is ODA with rebates and assistance so no good quoting FDA trial data etc.

This announcement should be a double banger as long as IGF results are released with the safety together etc.

Remember; this is one of a few to come over the next 3 weeks so an initial jump should be followed another and another imo


JMO, Good Luck All!